Ultima Taps Genomics Titan to Fuel Germline Sequencing Disruption

FREMONT, CA – May 18, 2026 – In a move that signals a significant strategic expansion, Ultima Genomics has appointed renowned genetics leader Francisco De La Vega, DSc, as its new Vice President of Germline Genomics and Distinguished Scientific Fellow. The high-profile hire underscores Ultima's ambition to leverage its disruptive, low-cost sequencing platform beyond oncology and into the vast, rapidly growing field of inherited genetic analysis.

The appointment positions Ultima to challenge established players in a market critical for understanding genetic diseases, advancing population health, and enabling personalized medicine. By bringing in a figure of De La Vega's stature, the company is making a clear statement about its intent to not only provide affordable sequencing but also to lead the charge in its clinical application.

A Career Forged at the Forefront of Genomics

Dr. De La Vega brings over two decades of experience from the highest echelons of human genetics and bioinformatics. His career is a map of modern genomics' evolution, marked by senior leadership roles at companies that have defined the industry. Before joining Ultima, he served as Chief Technology Officer at Galatea Bio, a firm focused on building diverse global biobanks, and as Vice President of Hereditary Disease at Tempus AI, where he leveraged large-scale data to advance precision medicine in oncology.

Perhaps most notably, De La Vega was the Chief Scientific Officer at Fabric Genomics, where he was a driving force behind the development of AI-powered tools for genomic interpretation. His work there, particularly on the Fabric GEM algorithm, was pivotal in accelerating the diagnosis of rare genetic diseases by drastically reducing the time required to pinpoint disease-causing variants from complex genomic data. This expertise in translating raw sequence into clinical insight is considered a critical asset for Ultima's new venture.

His influence extends to foundational global projects that have shaped our understanding of the human genome. He played a leading role in the landmark 1000 Genomes Project, which created the first comprehensive map of human genetic variation, and was a key contributor to the International Cancer Genome Consortium's (ICGC) pan-cancer analysis. An Adjunct Professor at Stanford University and co-author of over 100 scientific papers with nearly 50,000 citations, De La Vega is a respected and influential voice in the scientific community.

Ultima's Bid to Reshape the Sequencing Landscape

Ultima Genomics emerged from stealth mode in 2022 with a staggering $600 million in funding and a bold mission: to drive down the cost of sequencing and unleash the full power of genomics at scale. The company's technology, centered on its second-generation UG200 instrument and Solaris 2.0 chemistry, employs a revolutionary architecture that departs from conventional methods to enable massive throughput at a fraction of the traditional cost.

This focus on radical cost reduction has already made waves in the fields of oncology and liquid biopsy, where frequent and deep sequencing is paramount. Now, the company is setting its sights on the germline market.

"We are thrilled to welcome Francisco to Ultima Genomics," said Gilad Almogy, Founder and CEO of Ultima. "His deep expertise in germline genomics and proven leadership in advancing genetic analysis technologies will be invaluable as we push the boundaries of genome sequencing. Francisco's vision aligns perfectly with our mission to make high-quality genomic information accessible and affordable, accelerating discoveries that can improve human health."

A New Front in the Germline Genomics Race

The germline genomics market—which encompasses newborn screening, carrier testing, and large-scale population health studies—has long been hampered by the high cost and logistical complexity of sequencing. Ultima's technology is poised to address this bottleneck directly. As national genomics initiatives and biobank projects seek to sequence millions of individuals to understand disease risk, a cost-effective, high-throughput platform is not just advantageous; it is essential.

In his own words, Dr. De La Vega saw the potential for a paradigm shift. "With the Company's second-generation UG200 instrument, the improvements of the Solaris 2.0 chemistry, and exceptional scalability roadmap, I saw a compelling opportunity to help Ultima advance germline genome sequencing," he stated. "As newborn screening, biobank sequencing, and national genomics initiatives continue to expand, technology that can deliver a combination of low cost, high accuracy and high throughput is essential to making genomic medicine accessible to all who can benefit."

This strategic move places Ultima in direct competition with industry giants like Illumina, whose platforms are the current standard in many clinical and research labs, as well as with long-read sequencing specialists like PacBio and Oxford Nanopore Technologies, which offer advantages in resolving complex structural variants often missed by short-read technologies.

Beyond Data Generation: The Challenge of Interpretation

Experts note that Ultima's recruitment of De La Vega is about more than just technology and market expansion; it is about addressing the core challenge of modern genomics. For years, the industry's primary focus was on reducing the cost of generating data. However, the true bottleneck has shifted from sequencing to interpretation—turning billions of genetic data points into a clear, actionable diagnosis or insight.

De La Vega's profound experience in developing AI and bioinformatics tools to automate and scale genome interpretation is precisely what's needed to bridge this gap. His appointment signals that Ultima's strategy is not merely to sell cheaper sequencing but to build an ecosystem where its low-cost data can be effectively and efficiently utilized in clinical and research settings. By integrating a leader in genomic interpretation into its highest ranks, Ultima is positioning itself to offer a more complete solution, transforming the promise of affordable genomics into a practical reality for patients and researchers worldwide.